These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28028194)

  • 1. Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Borgi L; McMullan C; Wohlhueter A; Curhan GC; Fisher ND; Forman JP
    Hypertension; 2017 Feb; 69(2):243-248. PubMed ID: 28028194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.
    McMullan CJ; Borgi L; Fisher N; Curhan G; Forman J
    Clin J Am Soc Nephrol; 2017 May; 12(5):807-816. PubMed ID: 28320765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Vitamin D on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Borgi L; McMullan C; Wohlhueter A; Curhan GC; Fisher ND; Forman JP
    Am J Hypertens; 2017 Feb; 30(2):124-129. PubMed ID: 28077419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
    George J; Carr E; Davies J; Belch JJ; Struthers A
    Circulation; 2006 Dec; 114(23):2508-16. PubMed ID: 17130343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial.
    Gaffo AL; Calhoun DA; Rahn EJ; Oparil S; Li P; Dudenbostel T; Feig DI; Redden DT; Muntner P; Foster PJ; Biggers-Clark SR; Mudano A; Sattui SE; Saddekni MB; Bridges SL; Saag KG
    Arthritis Rheumatol; 2021 Aug; 73(8):1514-1522. PubMed ID: 33779064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
    Saag KG; Fitz-Patrick D; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; Becker MA
    Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients.
    Dogan A; Yarlioglues M; Kaya MG; Karadag Z; Dogan S; Ardic I; Dogdu O; Kilinc Y; Zencir C; Akpek M; Ozdogru I; Oguzhan A; Kalay N
    Blood Press; 2011 Jun; 20(3):182-7. PubMed ID: 21133824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The APEX trial: Effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X.
    Lim TK; Noman A; Choy AMJ; Khan F; Struthers AD; Lang CC
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29080386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia.
    Meléndez-Ramírez G; Pérez-Méndez O; López-Osorio C; Kuri-Alfaro J; Espinola-Zavaleta N
    Endocr Res; 2012; 37(1):1-6. PubMed ID: 21977925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
    Doehner W; Schoene N; Rauchhaus M; Leyva-Leon F; Pavitt DV; Reaveley DA; Schuler G; Coats AJ; Anker SD; Hambrecht R
    Circulation; 2002 Jun; 105(22):2619-24. PubMed ID: 12045167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
    Stocker SL; Graham GG; McLachlan AJ; Williams KM; Day RO
    J Rheumatol; 2011 May; 38(5):904-10. PubMed ID: 21285173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular Function and Uric Acid-Lowering in Stage 3 CKD.
    Jalal DI; Decker E; Perrenoud L; Nowak KL; Bispham N; Mehta T; Smits G; You Z; Seals D; Chonchol M; Johnson RJ
    J Am Soc Nephrol; 2017 Mar; 28(3):943-952. PubMed ID: 27620990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.